BioAlliance Pharma submits clinical trial new drug application and announces results of its July 27th 2009 General Assembly Meeting

Paris, July 28, 2009 – BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced the submission of a Fentanyl Lauriad® clinical trial application to the French Drug Agency (AFSSaPS) and its approval by the Ethics Committee (Comité de Protection des Personnes). This Phase I clinical trial will recruit its first subjects before end 2009. Patented until 2030, Fentanyl Lauriad® is based on the same muco-adhesive technology already validated with Loramyc®, BioAlliance already marketed drug. This sustained release new product is dedicated to the treatment of cancer chronic pain.

Furthermore, BioAlliance Pharma's shareholders were invited to attend the Extraordinary and Ordinary General Assembly Meeting on July 27th 2009 to vote on a new governance structure with a Board of Directors and corresponding changes of the by-laws. A total of a 7,238,991 shares, representing 56.20% of existing shareholders, were attending or were represented at the Meeting. The resolution received 66.06% of the votes. As 66.67% were necessary to allow the structural changes, the current organisation of the Supervisory Board and Management Board will be maintained.

About BioAlliance Pharma

As a preferred partner for hospital-based specialists, BioAlliance Pharma is a specialty biopharmaceutical company which develops and markets innovative products, especially in the fields of opportunistic infections and chemotherapy complications. In areas where medical needs are insufficiently met, our targeted approaches help overcome drug resistance and improve patient health & quality of life. BioAlliance Pharma's ambition is to become a leading player in these fields by coupling innovation to patient needs.
For more information, visit the BioAlliance Pharma web site at *http://www.bioalliancepharma.com*.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.
BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forwardlooking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the reference document approved by the AMF on April 11 2008 under the number R. 08-021, which is available on the AMF website (http://www.amf-france.org) or on BioAlliance Pharma S.A.'s website (http://www.bioalliancepharma.com).

BioAlliance Pharma SA
Dominique Costantini, President and CEO
Tel.: +33 1 45 58 76 01
dominique.costantini@bioalliancepharma.com
Nicolas Fellmann, CFO
Tel.: +33 1 45 58 71 00
nicolas.fellmann@bioalliancepharma.com

ALIZE RP
Caroline Carmagnol
Tel.: +33 6 64 18 99 59
caroline@alizerp.com